Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost of treatment of primary biliary cirrhosis with ursodeoxycholic acid

This month's Alimentary Pharmacology & Therapeutics investigates the cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.

News image

Long-term use of ursodeoxycholic acid is the recommended therapy in primary biliary cirrhosis.

The lifetime effectiveness and cost-effectiveness of ursodeoxycholic acid in primary biliary cirrhosis have, however, not been assessed.

Dr Boberg and colleagues from Norway estimated the health outcomes and lifetime costs of a Norwegian cohort of primary biliary cirrhosis patients on ursodeoxycholic acid.

Norwegian primary biliary cirrhosis patients who were included in a 5-year open-label study of ursodeoxycholic acid therapy were subsequently followed up for up to 12 years.

The lifetime survival was estimated using a Weibull survival model.

There was a 82% probability that ursodeoxycholic acid entails greater life expectancy
Alimentary Pharmacology & Therapeutics

The survival benefit from ursodeoxycholic acid was based on a randomized clinical trial from Canada, comparing the effect of non-ursodeoxycholic acid and ursodeoxycholic acid.

Survival and costs of standard care vs. standard care plus ursodeoxycholic acid were simulated in a Markov model with death and liver transplantation as major events, invoking transition of a patient's state in the model.

The team analyzed the gain in life expectancy for a primary biliary cirrhosis patient on ursodeoxycholic acid compared with standard care was about 2 years.

The researchers found that lifetime treatment costs were EUR 151,403 and EUR 157,741 for patients with and without ursodeoxycholic acid, respectively.

A probabilistic sensitivity analysis indicated an 82% probability that ursodeoxycholic acid entails both greater life expectancy and lower costs than standard care.

Dr Boberg's team concludes, "The results of this study indicate that ursodeoxycholic acid therapy is a dominant strategy as it confers reduced morbidity and mortality, as well as cost savings, compared with standard therapy."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12435
21 August 2013

Go to top of page Email this page Email this page to a colleague

 01 July 2015

Advanced search
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 29 June 2015 
Rescue therapy in ulcerative colitis
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Fecal microbiota in pediatric IBD
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 24 June 2015 
Environmental risk in IBD
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
NAFLD risk in celiac disease
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection
 08 June 2015 
Short sleep duration and NAFLD
 08 June 2015 
Heritability in inflammatory bowel disease
 08 June 2015 
Eosinophilic esophagitis
 05 June 2015 
In-hospital mortality in patients with lower GI bleeding
 05 June 2015 
Scoring system for microscopic colitis
 05 June 2015 
H. pylori and myocardial infarction
 04 June 2015 
Mucosal healing in celiac disease and pregnancy
 04 June 2015 
Gastrointestinal microbiomes in Crohn's
 04 June 2015 
Dyspepsia in the community:

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us